Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PEPSICO, INC.

(PEP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PepsiCo : Frito-Lay to Spend $200 Million on Texas Plant Expansion

06/08/2021 | 05:00pm EDT


ę MT Newswires 2021
All news about PEPSICO, INC.
08:01aPEPSICO : Lay's Releases Limited-Edition Flavor Swap Lineup Inspired By Doritos ..
PR
07/23FACTBOX-U.S. companies raise product prices to tackle wage, raw material infl..
RE
07/22PEPSICO : Insider at PepsiCo (PEP) Makes Significant Sale of Stock
MT
07/22JPMorgan Chase names Citi's Hassan as chief marketing officer
RE
07/22PEPSICO : Cheetos And Bad Bunny Drop Exclusive adidas Fashion Collection, Inviti..
PR
07/21INSIDER TRENDS : Insider Adds to Selling Trend at PepsiCo
MT
07/21Coca-Cola leans on early pandemic lessons to prepare for Delta variant hit
RE
07/21Coca-Cola leans on early pandemic lessons to prepare for Delta variant hit
RE
07/21PEPSICO : 2020 DE&I Report Illustrates Company's Progressive Journey from Commit..
PR
07/19PEPSICO : Creating sustainable football fields in communities that need them mos..
PU
More news
Financials (USD)
Sales 2021 76 889 M - -
Net income 2021 8 448 M - -
Net Debt 2021 34 241 M - -
P/E ratio 2021 26,0x
Yield 2021 2,70%
Capitalization 217 B 217 B -
EV / Sales 2021 3,27x
EV / Sales 2022 3,13x
Nbr of Employees 291 000
Free-Float 73,9%
Chart PEPSICO, INC.
Duration : Period :
PepsiCo, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PEPSICO, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 157,07 $
Average target price 164,25 $
Spread / Average Target 4,57%
EPS Revisions
Managers and Directors
Ramon Luis Laguarta Chairman & Chief Executive Officer
Hugh F. Johnston Vice Chairman, Chief Financial Officer & EVP
Rene Lammers Chief Science Officer & Executive Vice President
Seth Cohen Chief Information Officer & Senior Vice President
Pietro Antonio Tataranni Chief Medical Officer & Senior VP-Life Sciences